Table 21.
One-, Two-, Three-, Four-, Five-, and Ten-Year Relative Survival Rates†‡ for Selected Malignant Brain and Central Nervous System Tumors by Histology, SEER 18 Registries, 1995-2009§
| 1-Yr |
2-Yr |
3-Yr |
4-Yr |
5-Yr |
10-Yr |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Histology | N | % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI |
| Pilocytic astrocytoma | 2,967 | 97.8 | (97.2-98.3) | 96.6 | (95.9-97.3) | 95.6 | (94.7-96.4) | 94.8 | (93.8-95.6) | 94.1 | (93.1-95.1) | 91.4 | (89.8-92.8) |
| Diffuse astrocytoma | 5,430 | 71.6 | (70.3-72.8) | 60.7 | (59.4-62.1) | 54.5 | (53.1-56.0) | 50.1 | (48.6-51.5) | 47.1 | (45.6-48.6) | 36.0 | (34.2-37.8) |
| Anaplastic astrocytoma | 3,173 | 60.1 | (58.3-61.8) | 41.5 | (39.6-43.3) | 33.3 | (31.5-35.1) | 29.1 | (27.4-30.9) | 25.9 | (24.2-27.7) | 17.6 | (15.7-19.5) |
| Glioblastoma | 25,628 | 35.7 | (35.1-36.3) | 13.6 | (13.2-14.1) | 7.8 | (7.4-8.1) | 5.7 | (5.4-6.1) | 4.7 | (4.4-5.0) | 2.3 | (2.0-2.7) |
| Oligodendroglioma | 2,978 | 94.2 | (93.2-95.0) | 89.9 | (88.7-91.0) | 85.7 | (84.3-87.0) | 82.1 | (80.5-83.6) | 79.1 | (77.3-80.7) | 63.2 | (60.5-65.7) |
| Anaplastic oligodendroglioma | 1,165 | 81.0 | (78.6-83.3) | 66.9 | (64.0-69.7) | 59.8 | (56.7-62.8) | 54.3 | (51.1-57.4) | 49.4 | (46.1-52.6) | 34.2 | (29.8-38.5) |
| Ependymal tumors | 2,264 | 93.7 | (92.6-94.7) | 89.4 | (87.9-90.7) | 86.2 | (84.5-87.7) | 83.9 | (82.0-85.6) | 82.5 | (80.5-84.3) | 77.6 | (74.9-80.1) |
| Oligoastrocytic tumors | 1,639 | 87.9 | (86.2-89.5) | 76.6 | (74.4-78.8) | 70.2 | (67.7-72.5) | 64.5 | (61.8-67.1) | 60.2 | (57.3-63.0) | 47.2 | (43.5-50.9) |
| Glioma malignant, NOS | 3,644 | 61.9 | (60.2-63.5) | 50.4 | (48.7-52.1) | 47.0 | (45.2-48.7) | 44.7 | (42. 9-46.4) | 43.3 | (41.5-45.1) | 38.3 | (36.2-40.4) |
| Neuronal and mixed neuronal-glial tumors | 523 | 90.6 | (87.5-93.0) | 82.6 | (78.7-85.9) | 79.1 | (74.9-82.8) | 75.4 | (70.8-79.4) | 74.6 | (69.8-78.7) | 60.1 | (53.1-66.3) |
| Embryonal tumors | 2,464 | 82.2 | (80.6-83.7) | 72.0 | (70.1-73.8) | 67.1 | (65.0-69.0) | 63.8 | (61.7-65.8) | 61.2 | (59.0-63.3) | 54.2 | (51.7-56.6) |
| Lymphoma | 4,142 | 47.8 | (46.2-49.3) | 38.7 | (37.1-40.3) | 34.0 | (32.5-35.6) | 30.9 | (29.3-32.4) | 28.4 | (26.8-30.0) | 21.1 | (19.2-23.1) |
| Total: All Brain and Other Nervous System | 60,984 | 57.5 | (57.1-57.9) | 43.2 | (42.8-43.6) | 38.2 | (37.8-38.6) | 35.5 | (35.1-35.9) | 33.8 | (33.3-34.2) | 28.0 | (27.5-28.5) |
† The cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.
‡ Rates are an estimate of the percentage of patients alive at one, two, three, four, five, and ten year, respectively.
§ Estimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub (1973-2009 varying) - Linked To County Attributes - Total U.S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2012, based on the November 2011 submission.
Includes histologies not listed in this table.
Abbreviation: SEER, Survival, Epidemiology and End Results; CI, confidence interval; NOS, not otherwise specified.